@entity6337 of XXXX inhibitors: Exclusively due to UVA radiation and rapidly regressive.

@entity1 @entity6337 @entity5458 @entity817 @entity320 @entity5457
BACKGROUND: New targeted @entity320 therapies such as @entity817 inhibitors have shown high and promising clinical benefit but have cutaneous side-effects, including photosensitivity, which is triggered in the UVA radiation spectrum. However, visible spectrum implication has not yet been investigated. We conducted a study to determine whether visible light also contributes to the @entity6337 action spectrum of @entity5457 . The secondary end points were to determine the time to complete regression of the @entity6337 post- @entity5457 discontinuation and whether there was a significant difference between the UVA radiation immediate reactivity cut-offs, in @entity1 treated with @entity5457 vs. those treated with @entity5458 . METHOD: This prospective, observational study included @entity1 with @entity817 mutant metastatic @entity320 : 34 @entity1 treated with @entity5457 and 9 with @entity5458 . RESULTS: The visible-light phototest results in @entity1 treated with @entity5457 were all negative before and after 2 months of treatment. The UVA radiation phototests conducted 1 or 2 weeks post- @entity5457 discontinuation in 4 @entity1 showed a normalised UVA-radiation reactivity cut-off. UVA radiation phototests after 2 months of treatment were conducted for all @entity1 . The UVA radiation reactivity cut-off had been lowered for 30 @entity1 (88%) on @entity5457 and 3 @entity1 (33%) on @entity5458 . The median UVA radiation reactivity cut-off was 12  J/cm(2) for the @entity1 on @entity5457 and 20  J/cm(2) for the @entity1 on @entity5458 . CONCLUSION: @entity817 inhibitor @entity6337 is exclusively triggered by UVA radiation and resolves rapidly post-treatment discontinuation. A significant difference between the UVA immediate reactivity cut-offs, @entity5457 vs. @entity5458 , explains the difference in the clinical photosensitivity rates reported in the clinical trials.
